AnaptysBio, Inc. (ANAB) Rating Increased to Buy at Zacks Investment Research

Zacks Investment Research upgraded shares of AnaptysBio, Inc. (NASDAQ:ANAB) from a hold rating to a buy rating in a research report sent to investors on Tuesday morning. Zacks Investment Research currently has $24.00 price objective on the biotechnology company’s stock.

According to Zacks, “AnaptysBio, Inc. is a biotechnology company. It involved in the discovery and development of therapeutic antibodies for inflammation and immuno-oncology primarily in the Unites states. AnaptysBio, Inc. is based in San Diego, California. “

Several other equities research analysts also recently weighed in on the stock. Robert W. Baird assumed coverage on shares of AnaptysBio in a research note on Monday, July 10th. They set an outperform rating and a $36.00 target price on the stock. Stifel Nicolaus upped their target price on shares of AnaptysBio from $30.00 to $35.00 and gave the stock a buy rating in a research note on Tuesday, May 2nd. Finally, Credit Suisse Group reaffirmed an outperform rating and set a $34.00 target price on shares of AnaptysBio in a research note on Tuesday, April 18th. Six equities research analysts have rated the stock with a buy rating, AnaptysBio currently has an average rating of Buy and a consensus target price of $33.67.

Shares of AnaptysBio (ANAB) traded up 4.60% during trading on Tuesday, hitting $22.27. 92,148 shares of the stock were exchanged. AnaptysBio has a one year low of $15.17 and a one year high of $30.71. The stock’s 50 day moving average price is $24.38 and its 200-day moving average price is $24.48. The company’s market cap is $453.02 million.

AnaptysBio (NASDAQ:ANAB) last announced its earnings results on Thursday, August 10th. The biotechnology company reported ($0.13) earnings per share for the quarter, topping the consensus estimate of ($0.42) by $0.29. The business had revenue of $7 million for the quarter, compared to analysts’ expectations of $3.45 million. On average, analysts predict that AnaptysBio will post ($1.96) EPS for the current year.

ILLEGAL ACTIVITY WARNING: This piece of content was posted by Community Financial News and is the sole property of of Community Financial News. If you are viewing this piece of content on another publication, it was stolen and republished in violation of US & international copyright & trademark law. The original version of this piece of content can be viewed at https://www.com-unik.info/2017/08/18/anaptysbio-inc-anab-rating-increased-to-buy-at-zacks-investment-research.html.

In other AnaptysBio news, major shareholder Ventures Vii L. P. Avalon sold 37,040 shares of the stock in a transaction that occurred on Wednesday, July 26th. The shares were sold at an average price of $24.35, for a total value of $901,924.00. The sale was disclosed in a filing with the SEC, which is available through this link. Also, major shareholder Holdings A/S Novo sold 491,294 shares of the stock in a transaction that occurred on Monday, August 7th. The shares were sold at an average price of $21.12, for a total transaction of $10,376,129.28. Following the completion of the sale, the insider now directly owns 2,952,527 shares in the company, valued at $62,357,370.24. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 777,640 shares of company stock worth $16,705,386.

Several large investors have recently made changes to their positions in the stock. Frazier Management LLC purchased a new stake in shares of AnaptysBio during the first quarter worth approximately $102,354,000. Perceptive Advisors LLC purchased a new stake in shares of AnaptysBio during the first quarter worth approximately $24,474,000. Hamilton Lane Advisors LLC purchased a new stake in shares of AnaptysBio during the first quarter worth approximately $11,213,000. Artal Group S.A. increased its stake in shares of AnaptysBio by 459.4% in the second quarter. Artal Group S.A. now owns 250,000 shares of the biotechnology company’s stock worth $5,983,000 after buying an additional 205,310 shares in the last quarter. Finally, Marshall Wace North America L.P. purchased a new stake in shares of AnaptysBio during the first quarter worth approximately $6,924,000. 71.56% of the stock is currently owned by institutional investors.

About AnaptysBio

AnaptysBio, Inc is a United States-based biotechnology company. The Company is engaged in developing antibody product candidates focused on unmet medical needs in inflammation and immuno-oncology. The Company develops its product candidates using its antibody discovery technology platform, which is designed to replicate, in vitro, the natural process of antibody generation.

Get a free copy of the Zacks research report on AnaptysBio (ANAB)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for AnaptysBio (NASDAQ:ANAB)

What are top analysts saying about AnaptysBio Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for AnaptysBio Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit